InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 202484

Tuesday, 01/13/2015 11:32:25 AM

Tuesday, January 13, 2015 11:32:25 AM

Post# of 345890

We should ask them if they are the same Finken and Schlecht from CSM the company that had PPHM's 2nd ln NSCLC clinical trial sabotaged by JB who went to school with Schlecht and who's CEO Finken took over our trial WITHOUT looking back.

Contact

Wonder what they would reply if they get that question 200 times :)

Or is Finken busy to prepare a new ship to let the old one sink just in time with BK while making quick expanses on CSM that will the sell-out its assets to the new company for an apple and an egg?

Leaving nothing for PPHM. Would it be that simple?



I agree 100% and if I were to do business with a brand spanking new CRO, I would want to know of their past history of those in charge. Most small biotechs are not going to research and dig deeper for all the information that exists on CSM, though its easy enough to do a quick search but this new CRO is based close to Washington DC and political as it can get but I think everyone should send this new company a message and ask those exact words:

We should ask them if they are the same Finken and Schlecht from CSM the company that had PPHM's 2nd ln NSCLC clinical trial sabotaged by JB who went to school with Schlecht and who's CEO Finken took over our trial WITHOUT looking back.

Link posted again to ask above question
and if they are the same, then are there laws/rules/regulations or even basic ethical disclosures that they must report on any legal documents pertaining to their new company... I think yes

---------------------------------------------------------

Now I'm sure Peregrine is prepared when they went searching for a new CRO to do business with, but if I went bankrupt its almost impossible to become a new home owner with that on your record and if CSM goes under, how much is the next small biotech risking by dealing with the likes of Center Point Clinical Services?

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News